Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

Background

Coronavirus disease 2019 has highlighted deficiencies in the testing capacity of many developed countries during the early stages of pandemics. Here we describe a strategy using pan-family viral assays to improve early accessibility of large-scale nucleic acid testing.

Methods

Coronaviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were used as a case study for assessing utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to 60 reference coronaviruses, including SARS-CoV-2. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high-quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression.

Results

Because of common HCoV species, a Pan-CoV assay would return false positives for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease. One-half of reported Pan-CoV assays identify SARS-CoV-2 and with small adjustments can accommodate diverse variation observed in animal coronaviruses. The target region of 1 well-established Pan-CoV assay is highly resistant to mutation compared to species-specific SARS-CoV-2 reverse transcriptase-polymerase chain reaction assays.

Conclusions

Despite cross-reactivity with common pathogens, pan-family assays may greatly assist management of emerging pandemics through prioritization of high-resolution testing or isolation measures. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation. A strategic stockpile of pan-family assays may improve containment of novel diseases before the availability of species-specific assays.

Article activity feed

  1. SciScore for 10.1101/2020.05.24.20112318: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Sequences for a total of 60 species were identified (Supplementary Table 1), including the 7 species known to infect humans (HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2).
    HCoV-NL63
    suggested: RRID:CVCL_RW88)
    Software and Algorithms
    SentencesResources
    Review of common HCoV epidemiolocal characteristics: A search using the terms “HCoV” “epidemiology” and “asymptomatic” was performed in PubMed to identify studies describing HCoV infection characteristics.
    PubMed
    suggested: (PubMed, RRID:SCR_004846)
    Validation and modification of a reported Pan-CoV assays: Coronavirus-family reference sequences were identified and downloaded from the NCBI Virus database5
    NCBI Virus
    suggested: (NCBI Virus, RRID:SCR_018253)
    Pan-coronavirus assay primer targets were derived from four reported assays6-9 and aligned with the SARS-CoV-2 reference genome (NC_045512) to assess consensus between sequences using the Clustal Omega Multiple Sequence Alignment tool10.
    Clustal Omega
    suggested: (Clustal Omega, RRID:SCR_001591)
    The nucleic acid sequence and predicted protein sequence for each species was aligned and assessed for identity with Pan-CoV primer targets using the software package Geneious Prime 2020.1.2 (https://www.geneious.com).
    https://www.geneious.com
    suggested: (Geneious, RRID:SCR_010519)
    Analysis was performed with the R Biostrings package12 to identify mismatches in the primer target sites.
    Biostrings
    suggested: (Biostrings, RRID:SCR_016949)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This limitation can be mitigated through multiple strategies, most simply application of this tool as a first-line screen prior to confirmatory analysis with a more specific test. This would allow short-supply specific tests to be reserved as a confirmatory, rather than a primary tool, enabling a higher-throughput screen of large populations at ports-of-entry or for contact tracing during the early stages of pandemic. An alternative strategy, not reliant on the presence of a specific test, would be the addition of a second exclusionary reaction targeting known common species30, though this may not be an effective tool where a novel pathogen is highly genetically similar to a common species and may be overly burdensome for high-throughput population screening. During the initial roll-out of SARS-CoV-2 testing kits by the CDC, several laboratories experienced disruptions due to faulty testing kits31. Pan-family assays, developed prior to an outbreak, would have a relaxed timeframe for test development, ensuring best-practice validation, quality control procedures, regulatory certification and laboratory accreditation can be achieved. Pan-family assays may also have additional ongoing utility as a fallback in the case of quality control issues or disease mutations compromising the accuracy of specific assay detection32. By targeting highly conserved regions and accommodating silent mutations, pan-family assays can be expected to be less prone to mutation induced errors, though r...

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.